北京時間2019年08月01日21時57分,Anthera製藥(ANTH.us)股票出現波動,股價急速下挫16.67%。截至發稿,該股報0.040美元/股,成交量4466股,換手率0.02%,振幅19.79%。
最新的2018-03-31數據顯示,該股實現營業收入0.00美元,淨利潤-7.72百萬美元,每股收益-0.42美元,毛利-161000.00美元,市盈率-0.03倍。
機構評級方面,目前暫無機構對該股做出“買入、持有、賣出”建議。
Anthera製藥股票所在的生物技術行業中,整體漲幅爲1.11%。其相關個股中,Vanda Pharmaceuticals Inc、AVEO製藥公司、Regulus Therapeutics Inc漲幅較大,Can Fite Biofarma Ltd、Delmar Pharmaceuticals Inc、Sellas Life Sciences Group Inc較爲活躍,換手率分別爲34.38%、5.43%、4.52%,振幅較大的相關個股有Can Fite Biofarma Ltd、Nanostring Technologies Inc、Aileron Therapeutics Inc,振幅分別爲20.70%、19.72%、19.50%。
Anthera製藥公司簡介:Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.
(以上內容爲自選股智能機器寫手Money Call完成,僅作爲用戶看盤參考,不作爲交易依據。)